After the European Medicines Agency (EMA) raised a safety signal for semaglutide, shares in Denmark’s Novo Nordisk dropped in the Copenhagen market. Semaglutide is the active ingredient in Novo Nordisk’s diabetes and obesity medications.
After a Danish media outlet reported that the European Medicines Agency (EMA) had raised the safety signal, which is a means to monitor potential bad events from the usage of approved pharmaceuticals, shares in Denmark’s Novo dropped more than 2% in a weaker Copenhagen market.
Semaglutide, the active ingredient in Novo Nordisk’s well-known diabetic and obesity medications Ozempic and Wegovy, was flagged as having a thyroid cancer safety signal by the European Union’s drug watchdog last month, according to a statement released on Thursday by the company.
A warning from EMA does not necessarily imply that any documented adverse effects are brought on by the medication.
“Novo Nordisk is aware of the signal and the request by EMA and will deliver a thorough assessment of all relevant data to elucidate this topic,” said Lars Otto Andersen-Lange, the company’s head of media relations.
According to Andersen-Lange, pointed to an EMA statement dated May 8 that raised a thyroid cancer safety signal for a number of medications in the GLP-1 class, including semaglutide.
Large-scale clinical trials and post-marketing surveillance, however, have not revealed a “causal association” between semaglutide and thyroid cancer, he claimed.
“Patient safety has top priority for Novo Nordisk, and we take all reports about adverse events from use of our medicines very seriously,” continued Andersen-Lange.
GLP-1 medications from rival companies Eli Lilly, Astrazeneca, and Sanofi were also included in the EMA’s safety signal.
It is most likely way too early to express grave concern about this. However, it’s excellent that they are investigating it, according to Sydbank analyst Soren Lontoft Hansen.
Conclusion
The European Medicines Agency (EMA) has raised a safety signal for semaglutide, the active ingredient in Novo Nordisk’s diabetes and obesity medications. Shares in Denmark’s Novo dropped more than 2% in the weaker Copenhagen market after the EMA raised the signal. Semaglutide, the active ingredient in Novo Nordisk’s medications Ozempic and Wegovy, was flagged as having a thyroid cancer safety signal by the European Union’s drug watchdog last month. Novo Nordisk is aware of the EMA’s warning and will conduct a thorough assessment of all relevant data. Large-scale clinical trials and post-marketing surveillance have not revealed a “causal association” between semaglutide and thyroid cancer. Novo Nordisk is taking patient safety very seriously and is investigating the issue.
 raised a safety signal for semaglutide, shares in Denmark's Novo Nordisk dropped in the Copenhagen){kind=link}